Pulse Biosciences, Inc. – NASDAQ:PLSE
Pulse Biosciences stock price today
$15.85
-2.17
-12.04%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Pulse Biosciences stock price monthly change
-3.01%
month
Pulse Biosciences stock price quarterly change
-3.01%
quarter
Pulse Biosciences stock price yearly change
+40.34%
year
Pulse Biosciences key metrics
Market Cap | 1.07B |
Enterprise value | 88.37M |
P/E | -2.1 |
EV/Sales | 62.72 |
EV/EBITDA | -1.01 |
Price/Sales | 98.98 |
Price/Book | -62.04 |
PEG ratio | -0.08 |
EPS | -0.81 |
Revenue | N/A |
EBITDA | -44.02M |
Income | -42.54M |
Revenue Q/Q | N/A |
Revenue Y/Y | 579.68% |
Profit margin | -6371.47% |
Oper. margin | -6340.95% |
Gross margin | -907.59% |
EBIT margin | -6340.95% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePulse Biosciences stock price history
Pulse Biosciences stock forecast
Pulse Biosciences financial statements
| Jun 2023 | 0 | -9.91M | |
|---|---|---|---|
| Sep 2023 | 0 | -10.56M | |
| Dec 2023 | 1.74M | -11.93M | -685.8% |
| Mar 2024 | 0 | -10.13M |
| 2025 | 23.36M | -28.82M | -123.35% |
|---|---|---|---|
| 2026 | 34.46M | -22.57M | -65.51% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 74757000 | 14.25M | 19.07% |
|---|---|---|---|
| Sep 2023 | 65945000 | 13.8M | 20.93% |
| Dec 2023 | 60804000 | 16.44M | 27.04% |
| Mar 2024 | 49164000 | 12.87M | 26.19% |
| Jun 2023 | -9.20M | -16K | 13.86M |
|---|---|---|---|
| Sep 2023 | -10.48M | -23K | 2.14M |
| Dec 2023 | -6.77M | -43K | 798K |
| Mar 2024 | -9.78M | -5K | 305K |
Pulse Biosciences alternative data
| Aug 2023 | 61 |
|---|---|
| Sep 2023 | 61 |
| Oct 2023 | 61 |
| Nov 2023 | 61 |
| Dec 2023 | 61 |
| Jan 2024 | 61 |
| Feb 2024 | 61 |
| Mar 2024 | 61 |
| Apr 2024 | 61 |
| May 2024 | 61 |
| Jun 2024 | 56 |
| Jul 2024 | 56 |
Pulse Biosciences other data
3.51%
-3.10%
of PLSE is owned by hedge funds
13
-14
1.30M
-1.15M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 10000 | 0 |
| Jul 2024 | 2686349 | 0 |
| Dec 2024 | 111310 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | DUGGAN ROBERT W director, 10 percent owner: | Common Stock | 55,256 | $17.18 | $949,298 | ||
Purchase | DUGGAN ROBERT W director, 10 percent owner: | Common Stock | 50,000 | $17.42 | $871,000 | ||
Purchase | DUGGAN ROBERT W director, 10 percent owner: | Common Stock | 6,054 | $16.74 | $101,344 | ||
Purchase | DUGGAN ROBERT W director, 10 percent owner: | Warrant (right to buy) | 2,593,912 | $11 | $28,533,032 | ||
Purchase | ZANGANEH MAHKAM director | Warrant (right to buy) | 30,121 | $11 | $331,331 | ||
Purchase | DUGGAN ROBERT W director, 10 percent owner: | Warrant (right to buy) | 34,510 | $11 | $379,610 | ||
Purchase | DUGGAN ROBERT W director, 10 percent owner: | Warrant (right to buy) | 24,656 | $11 | $271,216 | ||
Purchase | DANAHY KEVIN PATRICK officer: Chief Commercial Officer | Warrant (right to buy) | 325 | $11 | $3,575 | ||
Purchase | LEVINSON MITCHELL E. officer: Chief St.. | Warrant (right to buy) | 161 | $11 | $1,771 | ||
Purchase | BARRETT BURKE THOMAS director, officer: President an.. | Warrant (right to buy) | 543 | $11 | $5,973 |
| Patent |
|---|
Application Filling date: 1 Feb 2022 Issue date: 19 May 2022 |
Application Filling date: 13 Jan 2022 Issue date: 5 May 2022 |
Grant Filling date: 19 Sep 2017 Issue date: 22 Feb 2022 |
Application Filling date: 27 Jul 2020 Issue date: 27 Jan 2022 |
Application Filling date: 9 Oct 2019 Issue date: 13 Jan 2022 |
Application Filling date: 20 Mar 2020 Issue date: 30 Dec 2021 |
Application Filling date: 10 Aug 2021 Issue date: 2 Dec 2021 |
Grant Filling date: 14 Jan 2019 Issue date: 9 Nov 2021 |
Grant Utility: Methods and devices for stimulating an immune response using nanosecond pulsed electric fields Filling date: 23 Jun 2020 Issue date: 6 Jul 2021 |
Grant Utility: High-voltage analog circuit pulser Filling date: 22 Nov 2019 Issue date: 6 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Darrin R. Uecker (1966) Pres, Chief Executive Officer & Director | $690,450 |
| Ms. Sandra A. Gardiner (1966) Executive Vice President of Fin. & Admin., Chief Financial Officer, Sec. and Treasurer | $572,460 |
Mr. Edward A. Ebbers (1960) Executive Vice President & GM of Dermatology | $424,950 |
| Mr. Mitchell E. Levinson (1960) Chief Strategy Officer & Director | $138,020 |
-
What's the price of Pulse Biosciences stock today?
One share of Pulse Biosciences stock can currently be purchased for approximately $15.85.
-
When is Pulse Biosciences's next earnings date?
Unfortunately, Pulse Biosciences's (PLSE) next earnings date is currently unknown.
-
Does Pulse Biosciences pay dividends?
No, Pulse Biosciences does not pay dividends.
-
How much money does Pulse Biosciences make?
Pulse Biosciences has a market capitalization of 1.07B.
-
What is Pulse Biosciences's stock symbol?
Pulse Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "PLSE".
-
What is Pulse Biosciences's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Pulse Biosciences?
Shares of Pulse Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Pulse Biosciences's key executives?
Pulse Biosciences's management team includes the following people:
- Mr. Darrin R. Uecker Pres, Chief Executive Officer & Director(age: 59, pay: $690,450)
- Ms. Sandra A. Gardiner Executive Vice President of Fin. & Admin., Chief Financial Officer, Sec. and Treasurer(age: 59, pay: $572,460)
- Mr. Edward A. Ebbers Executive Vice President & GM of Dermatology(age: 65, pay: $424,950)
- Mr. Mitchell E. Levinson Chief Strategy Officer & Director(age: 65, pay: $138,020)
-
How many employees does Pulse Biosciences have?
As Jul 2024, Pulse Biosciences employs 56 workers, which is 8% less then previous quarter.
-
When Pulse Biosciences went public?
Pulse Biosciences, Inc. is publicly traded company for more then 9 years since IPO on 18 May 2016.
-
What is Pulse Biosciences's official website?
The official website for Pulse Biosciences is pulsebiosciences.com.
-
Where are Pulse Biosciences's headquarters?
Pulse Biosciences is headquartered at 3957 Point Eden Way, Hayward, CA.
-
How can i contact Pulse Biosciences?
Pulse Biosciences's mailing address is 3957 Point Eden Way, Hayward, CA and company can be reached via phone at +51 09064600.
Pulse Biosciences company profile:
Pulse Biosciences, Inc.
pulsebiosciences.comExchange:
NASDAQ
Full time employees:
56
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
3957 Point Eden Way
Hayward, CA 94545
Hayward, CA 94545
CIK: 0001625101
ISIN: US74587B1017
CUSIP: 74587B101
